In 50 randomised people with Stargardt disease plus 54 natural history cases, oral gildeuretinol acetate slowed atrophic lesion growth vs untreated (0.182 vs 0.232 mm/y; difference −0.050; 21.6% relative reduction). Versus placebo only: 14.9%. No treatment-related serious AEs.
RCTn = 50
Kay et al. Safety and Effects of Gildeuretinol Acetate on Retinal Atrophic Lesions in Stargardt Disease: The TEASE-1 Randomized Clinical Trial